Wednesday, June 7, 2023
  • English
  • Marathi
No Result
View All Result
Daily PRABHAT
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science
Daily PRABHAT
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
Home Headlines

Mansukh Mandaviya’s important information regarding approval to Covaxin

by Digital Desk
2 years ago
in Headlines, National, Top News
A A
Bharat Biotech awaits feedback from WHO for Covaxin’s emergency use listing
Share on FacebookShare on Twitter

New Delhi – Union Health Minister Mansukh Mandaviya on Tuesday said that approval for Hyderabad-based Bharat Biotech’s COVID-19 vaccine Covaxin will be given on the basis of the meeting which will be convened by the World Health Organization (WHO) today.

“WHO has a system in which there is a technical committee which has approved it (Covaxin) while the other committee is meeting today. The approval for Covaxin will be given on the basis of today’s meeting,” said Union Health Minister during a press briefing here.

Earlier this month, WHO chief scientist Dr Soumya Swaminathan had said that WHO’s technical advisory group will meet on October 26 to consider emergency use listing (EUL) for Covaxin.

The WHO last week had said a vaccine recommended by it for emergency use must be evaluated thoroughly.

“We are aware that many people are waiting for WHO’s recommendation for Covaxin to be included in the COVID19 Emergency Use Listing, but we cannot cut corners – before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective,” the organisation had said.

The WHO had said that the timeframe for the WHO Emergency Use Listing procedure depends on how quickly a company producing the vaccine is able to provide the required data.

“The timeframe for the WHO Emergency Use Listing procedure is dependent on how quickly a company producing the vaccine is able to provide the data required for WHO to evaluate the vaccine’s quality, safety, efficacy and its suitability for low- and middle-income countries,” it said.

Bharat Biotech has been submitting data to WHO on a rolling basis and submitted additional information at WHO’s request on September 27.

Covaxin, India’s first indigenous COVID-19 vaccine, has been developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Tags: coronacorona updatenational
ShareTweetSendShareSend

Latest News

Amit Shah reviews progress of computerisation of Central Registrar of Cooperative Societies’ office

Raja Bilal: Maestro of Kashmiri folk music and a bridge between traditions

Coromandel Express departs from West Bengal’s Shalimar to Chennai, first time after three-train accident in Odisha

Lights, Camera, Kashmir: Bollywood’s return to valley ignites tourism hope

“Show me if there is any party not joining hands with BJP…”: Former PM Deve Gowda

‘Pyaar Ka Punchnama’ actor Sonnalli Seygall ties knot with Ashesh Sajani; couple exudes charm in first official wedding photos

Nimrat Kaur shares what she learned while playing school counsellor in ‘School of Lies’

Park Chan-wook to produce Korean historical drama ‘War and Revolt’

Chris Hemsworth opens up about ‘Thor 4’, says “It became too silly”

Citadel: Varun Dhawan, Sikander Kher undergo intense action training in Serbia

New Delhi - Union Health Minister Mansukh Mandaviya on Tuesday said that approval for Hyderabad-based Bharat Biotech's COVID-19 vaccine Covaxin will be given on the basis of the meeting which will be convened by the World Health Organization (WHO) today. "WHO has a system in which there is a technical committee which has approved it (Covaxin) while the other committee is meeting today. The approval for Covaxin will be given on the basis of today's meeting," said Union Health Minister during a press briefing here. Earlier this month, WHO chief scientist Dr Soumya Swaminathan had said that WHO's technical advisory group will meet on October 26 to consider emergency use listing (EUL) for Covaxin. The WHO last week had said a vaccine recommended by it for emergency use must be evaluated thoroughly. "We are aware that many people are waiting for WHO's recommendation for Covaxin to be included in the COVID19 Emergency Use Listing, but we cannot cut corners - before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective," the organisation had said. The WHO had said that the timeframe for the WHO Emergency Use Listing procedure depends on how quickly a company producing the vaccine is able to provide the required data. "The timeframe for the WHO Emergency Use Listing procedure is dependent on how quickly a company producing the vaccine is able to provide the data required for WHO to evaluate the vaccine's quality, safety, efficacy and its suitability for low- and middle-income countries," it said. Bharat Biotech has been submitting data to WHO on a rolling basis and submitted additional information at WHO's request on September 27. Covaxin, India's first indigenous COVID-19 vaccine, has been developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
No Result
View All Result
  • Home
  • Latest News
  • National
  • International
  • Entertainment
  • Politics
  • Sports
  • Business
  • More
    • Health
    • Lifestyle
    • Technology
    • Science